inhaled PDE4 inhibitor

Joincare Pharmaceutical's inhaled PDE4 inhibitor is a preclinical small molecule candidate currently in the Pre-IND stage for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The drug is designed to inhibit the phosphodiesterase 4 (PDE4) enzyme, which is responsible for the degradation of cyclic adenosine monophosphate (cAMP) in inflammatory cells. By increasing intracellular cAMP levels, the inhibitor suppresses the release of pro-inflammatory cytokines and mediators, thereby reducing airway inflammation. The inhaled route of administration is intended to deliver the therapeutic agent directly to the lungs, maximizing local efficacy while minimizing the systemic gastrointestinal and central nervous system side effects often associated with oral PDE4 inhibitors like roflumilast. Joincare's program is described as having a similar therapeutic rationale to the dual PDE3/4 inhibitor ensifentrine (Ohtuvayre), though it specifically targets PDE4 to address airway inflammation.

Other names

inhaled PDE4 inhibitor吸入型PDE4抑制剂